Alizé Pharma: positive results from its Phase II clinical trial in Prader-Willi Syndrome

Graftys announces regulatory clearance in Australia and in Canada

OREGA presents its first-in-class CD39 checkpoint inhibitor at the AACR meeting

Alizé Pharma: positive results from its Phase II clinical trial in Prader-Willi Syndrome

Published by Octalfa at 26 April 2016

Categories

AlizeePharma_actu

Date26 April 2016

The study was aimed at evaluating the safety, tolerability and efficacy of AZP-531 in patients with Prader-Willi Syndrome.